S A Piha-Paul
Overview
Explore the profile of S A Piha-Paul including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
497
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Piha-Paul S, Tseng C, Tran H, Naing A, Dumbrava E, Karp D, et al.
ESMO Open
. 2025 Feb;
10(2):104136.
PMID: 39908697
Background: The ErbB family of receptor tyrosine kinases are key targets for antitumor therapy. Although neratinib, a pan-ErbB kinase inhibitor, is approved in ErbB2-positive breast cancer, drug resistance is common....
2.
Gouda M, Shunyakova J, Naing A, Dumbrava E, Hong D, Yuan Y, et al.
ESMO Open
. 2024 Jun;
9(6):103486.
PMID: 38914452
Background: Paclitaxel resistance limits durability of response in patients with initial clinical benefit. Overexpression of spleen tyrosine kinase (SYK) has been proposed as a possible resistance mechanism. This phase I...
3.
Phadnis S, Wang X, Daw N, Herzog C, Subbiah I, Zaky W, et al.
ESMO Open
. 2023 Oct;
8(6):101609.
PMID: 37879233
Background: Combined use of inhibitors of mammalian target of rapamycin (mTOR) and vascular endothelial growth factor (VEGF-2) receptors is a potential strategy to overcome resistance to either class of drugs...
4.
Uzunparmak B, Haymaker C, Raso G, Masciari S, Wang L, Lin H, et al.
Ann Oncol
. 2023 Aug;
34(11):1035-1046.
PMID: 37619847
Background: Human epidermal growth factor receptor 2 (HER2)-low is a newly defined category with HER2 1+ or 2+ expression by immunohistochemistry (IHC) and lack of HER2 gene amplification measured by...
5.
Jhaveri K, Eli L, Wildiers H, Hurvitz S, Guerrero-Zotano A, Unni N, et al.
Ann Oncol
. 2023 Aug;
34(10):885-898.
PMID: 37597578
Background: HER2 mutations are targetable alterations in patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC). In the SUMMIT basket study, patients with HER2-mutant MBC received neratinib monotherapy, neratinib +...
6.
Dumbrava E, Call S, Huang H, Stuckett A, Madwani K, Adat A, et al.
ESMO Open
. 2021 Sep;
6(5):100230.
PMID: 34479035
Background: Oncogenic mutations in PIK3CA are prevalent in diverse cancers and can be targeted with inhibitors of the phosphoinositide-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway. Analysis of circulating tumor...
7.
Cascone T, Sacks R, Subbiah I, Drobnitzky N, Piha-Paul S, Hong D, et al.
ESMO Open
. 2021 Mar;
6(2):100079.
PMID: 33721621
Background: Preclinical studies suggest that combining vandetanib (VAN), a multi-tyrosine kinase inhibitor of rearranged during transfection (RET) proto-oncogene, vascular endothelial growth factor receptor (VEGFR), and epidermal growth factor receptor (EGFR),...
8.
Hansen A, Massard C, Ott P, Haas N, Lopez J, Ejadi S, et al.
Ann Oncol
. 2018 Jul;
29(8):1807-1813.
PMID: 29992241
Background: Patients with castration-resistant prostate cancer derive only modest clinical benefit from available therapies. Blockade of the inhibitory programmed death 1 (PD-1) receptor by monoclonal antibodies has been effective in...
9.
Liu L, Toung J, Jassowicz A, Vijayaraghavan R, Kang H, Zhang R, et al.
Ann Oncol
. 2018 Apr;
29(6):1445-1453.
PMID: 29635542
Background: Targeted methylation sequencing of plasma cell-free DNA (cfDNA) has a potential to expand liquid biopsies to patients with tumors without detectable oncogenic alterations, which can be potentially useful in...
10.
Ott P, Piha-Paul S, Munster P, Pishvaian M, van Brummelen E, Cohen R, et al.
Ann Oncol
. 2017 Apr;
28(5):1036-1041.
PMID: 28453692
Background: Safety and efficacy of pembrolizumab, a humanized programmed death 1 monoclonal antibody, was assessed in KEYNOTE-028, a multicohort, phase Ib trial for patients with programmed death ligand 1 (PD-L1)-positive...